| Document |
Document Title |
|
JPH01142727A |
PURPOSE:To obtain a photoconductive film sensitive body high in sensitivity and low in residual potential and an electrophotographic sensitive body good in durability b incorporating at least one of styryl compounds specified in structur...
|
|
JPH01132586A |
NEW MATERIAL:Vitamin B2 acid lactone. USE:A red tide-controlling agent which has action to inhibit the microorganism causing red tide (Chattonella antiqua) from growing. PREPARATION:For example, 7,8-dimethyl-10-(2,3,4-trihydroxy-4-carbox...
|
|
JPH01104075A |
NEW MATERIAL:A flavin derivative shown by formula I (R1 is H or acyl; R2 and R3 are H or 1W4C lower alkyl; R4 is thiocyanato or mercapto). EXAMPLE: 6 Thiocyanato-2',3',4',3'-tetraacetylflavin. USE: Useful as a modifier for an electrode t...
|
|
JPS6434928A |
PURPOSE: To obtain a solid material by treating a water-based alkaline solution containing the solid material hardly soluble under a weak acidic or weak alkaline condition but relatively easily soluble in a strong alkaline condition in a...
|
|
JPS63239222A |
Use of pteridines and/or biochemical precursors thereof or of xanthine oxidase inhibitors for the treatment of hereditary degenerative retinal diseases, in particular retinopathy pigmentosa (RP), and preparation of a suitable medicament.
|
|
JPS63233984A |
NEW MATERIAL:The compound of formula I [one of R1 and R2 is group of formula II (n is 0 or 1; m is 1 or 2) and the other is OH]. EXAMPLE: N-(L-amethopteryl) L-cysteine. USE: A remedy for cancer. PREPARATION: The objective compound can be...
|
|
JPS63227588A |
NEW MATERIAL:A compound expressed by formula I [R1 is branched lower alkyl or acyloxy or lower alkyl substituted by formula II (R2 is lower alkyl). EXAMPLE: Diisopropyl N-[4-[[(2,4-diamino-6-pteridinyl)-methyl]-methylamino]- benzoyl]-L-g...
|
|
JPS63208521A |
Joint destruction associated with arthritic disease in warm blooded animals is treated with unexpected safety using 3,5-dichloromethotrexate. The therapeutic index therefor is unexpectedly enhanced through combination therapy using a pos...
|
|
JPS63188627A |
PURPOSE: To obtain excellent antiallergic and antiphlogistic agents containing at least one selected from flavin adenine dinucleotide, flavin mononucleotide and riboflavin as an essential ingredient. CONSTITUTION: At least one ingredient...
|
|
JPS6316390B2 |
|
|
JPS631314B2 |
Pharmaceutical preparations which contain pteridine derivatives of the formula I are described. They have a diuretic and antihypertensive action.
|
|
JPS62281878A |
NEW MATERIAL:A compound shown by formula I (one or two of X, Y and Z are N and the other is CH; R1 and R2 are H, lower alkyl or β-hydroxyethyl; n is 2 or 3) and an acid addition salt thereof. EXAMPLE: N-β-Dimethylaminoethyl 5-hydroxybe...
|
|
JPS6254403B2 |
Pharmaceutical compsns. capable of correcting deficiencies in serotonin metabolism compise 5-hydroxytryptophan(5HTP) in association with one or moe purine, pyriidine and/or pyridine deriVs. (I). Also claimed is the pepn. of an inosine-L-...
|
|
JPS62209062A |
NEW MATERIAL:A compound expressed by formula I [A, B, D, E and F are C or N; R1 and R2 are H, lower alkyl, lower alkoxy, nitro or lower alkyl substituted by a halogen; amino which may be substituted by OH, lower alkanoyl or toluenesulfon...
|
|
JPS62153753A |
PURPOSE: To obtain a desirable affinity gel, by constituting said gel of a copolymer based on glycidyl monovinyl ester A and alkylene glycol divinyl ester (B) and containing acriflavin bonded to the epoxy group of the A-component. CONSTI...
|
|
JPS62132881A |
Riboflavin of the formula I (I) is prepared by an improved process by condensing a 4,5-dimethyl-N-(D)-ribityl-2-phenylazoaniline of the formula II (II) where R is H, -CL, -NO2, -CH3 or -OCH3 in the o- or p-position, with barbituric acid ...
|
|
JPS62120386A |
Pteridine derivatives of general formula (I) in which R is hydrogen or methyl, i.e. aminopterin or methotrexate, are made by the action of a silazane on a pteridine derivative of formula (II)
|
|
JPS6281385A |
NEW MATERIAL:A compound shown by the formula I (A1 and A2 are H or ester residue; R is 1W5C alkyl; 1W5C alkylthio or OH) or its salt. EXAMPLE: N-[4[[2,4-Diamino-6-pteridinyl)methyl]methylamine]benzoyl]7-
meth ylthioglutamic acid shown by...
|
|
JPS624366B2 |
|
|
JPS6143329B2 |
A pharmaceutical composition for inducing diuresis, which composition comprises a diuretically-effective amount of the sulfuric acid half ester of 2,4,7-triamino-6-p-hydroxyphenyl pteridine or of a physiologically tolerable salt thereof ...
|
|
JPS6139948B2 |
|
|
JPS61189556A |
PURPOSE: To obtain the titled body having a high sensitivity and a less residual voltage and to improve an efficiency of a charge transportation of said by incorporating a specific compd. to the titled body. CONSTITUTION: The titled body...
|
|
JPS6133033B2 |
The process for the production of 2-amino-4-hydroxy-6-methylpteridine from 2,4,5-triamine-6-hydroxypyrimidine and 1,1-dichloroacetone which is characterized in that the 2,4,5-triamino-6-hydroxypyrimidine in the form of one of its stable ...
|
|
JPS61140585A |
Pteridines of the formula in which R2 denotes the piperazino or N-formylpiperazino group, R4 denotes a dialkylamino, phenylalkylamino, N-alkylphenylalkylamino, pyrrolidino, piperidino, morpholino, thiomorpholino, 1-oxidothiomorpholino, t...
|
|
JPS6124394B2 |
There is disclosed an improved process for the preparation of 10-deazaaminopterin and related compounds. In accordance with this process, 6-(bromomethyl)-2,4-pteridinediamine hydrobromide is reacted with triphenyl-phosphine to form a pho...
|
|
JPS6187620A |
PURPOSE: To prepare a transparent compounded drug of vitamin B2 butyric acid ester for soft capsule, preservable extremely stably for a long period without forming precipitate, and having unparallelled high titer, by dissolving vitamin B...
|
|
JPS6172766A |
2-Amino-3-cyano-5-dialkoxymethylpyrazine derivatives of the general formula III (III) where R1 and R2 are each hydrogen or a protective group usually employed for amino groups and R5 and R6 are each alkyl of 1 to 4 carbon atoms, or toget...
|
|
JPS613325B2 |
1534238 Treatment of malignancies with 10-deazaminopterin SRI INTERNATIONAL 4 March 1977 [5 March 1976] 09255/77 Heading A5B Leukemia, ascites tumour and other malignancies may be treated 10-deazaminopterin of formula: in the form of tab...
|
|
JPS6121096A |
PURPOSE: To obtain efficiently riboflavin, by cultivating a microorganism capable of producing the riboflavin using a lower aliphatic compound as a substrate, extracting the resultant culture with hot water, and cooling the resultant hot...
|
|
JPS611688A |
The present invention provides lipoidal biopterin and tetrahydrobiopterin compounds of the general structure:wherein-R is absent when ring B has two double bonds,-R is hydrogen when the two double bonds in ring B are absent, and-R' and R...
|
|
JPS6058725B2 |
Compsn. with diuretic and hypotensive activities comprises per unit dose, about 100-500mg of 4-(2-thenoyl)-2,3-di-chlorophenoxyacetic acid (I) or one its alkali metal salts, or base addn. salts and about 25-100mg. of triamterene (II) plu...
|
|
JPS60252456A |
An improved process for the preparation of riboflavin by condensation of a 4,5-dimethyl-N-(D)-ribityl-2-phenylazoaniline derivative with barbituric acid in the presence of an acidic condensing agent in an organic solvent, wherein a 4,5-d...
|
|
JPS60224623A |
The present invention relates to pharmaceutical preparations with cardiac, particularly anti-arrhythmic activity. These preparations comprise, as an active principle, at least one compound of formula I: where R represents a lipophilic ra...
|
|
JPS60202885A |
Pteridine compounds, useful as diuretics, of the formula +TR wherein R1 and R2 taken alone are, independently of each other, hydrogen, alkyl having from 1 to 6 carbon atoms, or benzyl, or wherein R1 and R2, taken together with the nitrog...
|
|
JPS60188387A |
2,4-Diaminopteridine derivatives and the pharmaceutically acceptable salts thereof having potent anticancer activity are disclosed. Said derivatives possess the structural formula: in which R and R min are as previously defined, provided...
|
|
JPS6036409B2 |
1405246 Potentiated antibacterial medicines WELLCOME FOUNDATION LTD 4 Aug 1972 [5 Aug 1971 1 Aug 1972] 36774/71 and 35817/72 Heading A5B Antibacterial compositions comprise a competitor of p-aminobenzoic acid or an inhibitor of dihydrofo...
|
|
JPS60146897A |
PURPOSE: To obtain a high-purity biopterin, easily, without using a column, by preparing an alkali metal salt of biopterin from an alkaline aqueous solution of crude biopterin by a specific method, dissolving the salt in water, and treat...
|
|
JPS60115584A |
Chain extended analogues of Methotrexate and Aminopterin having antitumor activity and low toxicity are soluble in water at a physiological pH ranging from 7.2-7.5.
|
|
JPS60500766A |
PCT No. PCT/EP84/00049 Sec. 371 Date Oct. 9, 1984 Sec. 102(e) Date Oct. 9, 1984 PCT Filed Feb. 27, 1984 PCT Pub. No. WO84/03699 PCT Pub. Date Sep. 27, 1984.Novel 3-amino-tetrahydro-1,3-thiazine-2,4-diones as well as skin treating composi...
|
|
JPS6078983A |
Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin having antitumor activity and low toxicity are soluble in water at a physiological pH ranging from 7.2-7.5.
|
|
JPS6025991A |
New 2-piperazino-pteridines of general formula are described wherein R1 represents a phenylalkylamino, alkylamino or dialkylamino group, a piperidino, morpholino, thiomorpholino, or 1-oxidothiomorpholino group, R2 represents a dialkylami...
|
|
JPS59186986A |
PURPOSE: To prepare the titled compound with decreased amount of solvent and simplified procedure, in high yield, by using 1',1'-dialkylsulfonyl-L-rhamnose as a starting raw material, and carrying out the reaction of the material continu...
|
|
JPS5939415B2 |
1474460 Indanones MERCK & CO Inc 7 Oct 1974 [11 Oct 1973 30 July 1974] 26849/76 Divided out of 1474459 Heading C2C The invention comprises compounds of formula wherein R is (a) Ph optionally substituted by NO 2 , OH, C 1-5 alkyl or alk...
|
|
JPS59112987A |
NEW MATERIAL:A 1',2'-diacyl-5,6,7,8-tetrahydro-L-biopterin of formula I (R1 and R2 are acyl). USE: A remedy for phenylketonuria and dihydropterin-reductase deficiency. PROCESS: A 1',2'-diacyl-L-biopterin of formula II is hydrogenated in ...
|
|
JPS59500914A |
(57) [Abstract] Since this gazette is application data in front of an electronic application, the data of an abstract is not recorded.
|
|
JPS58188886A |
Novel pteridinyl deriviatives of the formula are described; the meanings of the substituents are given in greater detail in the application. The novel compounds can be used for controlling undesired plant growth and prepared in a manner ...
|
|
JPS5831353B2 |
Process for the preparation of d,l-5-methyltetrahydrofolic acid and its salts of the formula 1 in which X is hydrogen, an alkali metal or the equivalent of an alkaline earth metal, by reduction of folic acid with NaBH4 and methylation of...
|
|
JPS5827797B2 |
There is disclosed an improved process for the preparation of 10-deazaaminopterin and related compounds. In accordance with this process, 6-(bromomethyl)-2,4-pteridinediamine hydrobromide is reacted with triphenyl-phosphine to form a pho...
|
|
JPS5896088A |
(57) [Abstract] Since this gazette is application data in front of an electronic application, the data of an abstract is not recorded.
|
|
JPS5883691A |
NEW MATERIAL:A compound of formulaI(R1, R2 are acyl). EXAMPLE: 1',2'-Diacetyl-(6R)-5,6,7,8-tetrahydro-L-biopterin. USE: A remedy for phenylketonurea and dihydropterin reductase deficiency. PREPARATION: 1',2'-Diacyl-L-biopterin of formula...
|
